CARLOS
SOLANO VERCET
CATEDRÁTICO/A DE UNIVERSIDAD
![Foto de CARLOS](/img/nophoto.png)
![Foto de Universitat Autònoma de Barcelona](/img/noimage_org.png)
Universitat Autònoma de Barcelona
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Universitat Autònoma de Barcelona (16)
2024
-
Torque Teno Virus plasma DNA load: a novel prognostic biomarker in CAR-T therapy
Bone Marrow Transplantation, Vol. 59, Núm. 1, pp. 93-100
2021
-
Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations
British Journal of Haematology, Vol. 194, Núm. 4, pp. 708-717
-
Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma
Cancer Medicine, Vol. 10, Núm. 10, pp. 3214-3223
2020
-
Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis
Leukemia and Lymphoma, pp. 1-10
-
Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies
Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 2, pp. 358-366
2019
-
Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study
The Lancet Haematology, Vol. 6, Núm. 2, pp. e89-e99
-
Author Correction: Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation (Bone Marrow Transplantation, (2019), 54, 7, (1133-1137), 10.1038/s41409-018-0422-z)
Bone Marrow Transplantation
-
Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation
Bone Marrow Transplantation
-
Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation
Biology of Blood and Marrow Transplantation, Vol. 25, Núm. 5, pp. 1022-1030
-
Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH)
European Journal of Haematology, Vol. 102, Núm. 6, pp. 465-471
2017
-
A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis
Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 7, pp. 1177-1185
2016
-
GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: Results of a multicenter study
Bone Marrow Transplantation
-
Umbilical cord blood transplantation in adults with advanced hodgkin's disease: High incidence of post-transplant lymphoproliferative disease
European Journal of Haematology, Vol. 96, Núm. 2, pp. 128-135
2013
-
Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach
Biology of Blood and Marrow Transplantation, Vol. 19, Núm. 1, pp. 69-74
2010
2009
-
Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: A phase II trial
Leukemia and Lymphoma, Vol. 50, Núm. 2, pp. 216-222